Our findings confirm upregulation of GCNT1 gene levels in prostate cancer tissue compared to normal or benign prostate tissue, and suggest GCNT1 may be upregulated in patients with increased risk of metastasis and those developing relapse to castrate resistant disease. This evidence concerns the gene GCNT1 and prostate cancer.